Celularity Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 99/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Celularity Inc's Score
Industry at a Glance
Industry Ranking
99 / 158
Overall Ranking
259 / 4582
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
6.000
Target Price
+217.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Celularity Inc Highlights
StrengthsRisks
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 201.64% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 54.22M.
Fairly Valued
The company’s latest PE is -0.44, at a medium 3-year percentile range.
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Ticker SymbolCELU
CompanyCelularity Inc
CEOHariri (Robert J)
Websitehttps://celularity.com/
FAQs
What is the current price of Celularity Inc (CELU)?
The current price of Celularity Inc (CELU) is 1.450.
What is the symbol of Celularity Inc?
The ticker symbol of Celularity Inc is CELU.
What is the 52-week high of Celularity Inc?
The 52-week high of Celularity Inc is 4.350.
What is the 52-week low of Celularity Inc?
The 52-week low of Celularity Inc is 1.001.
What is the market capitalization of Celularity Inc?
The market capitalization of Celularity Inc is 40.91M.
What is the net income of Celularity Inc?
The net income of Celularity Inc is -57.89M.
Is Celularity Inc (CELU) currently rated as Buy, Hold, or Sell?
According to analysts, Celularity Inc (CELU) has an overall rating of Buy, with a price target of 6.000.
What is the Earnings Per Share (EPS TTM) of Celularity Inc (CELU)?
The Earnings Per Share (EPS TTM) of Celularity Inc (CELU) is -3.327.